<DOC>
	<DOCNO>NCT02390531</DOCNO>
	<brief_summary>The purpose study find dose intravitreal bevacizumab lower currently use severe retinopathy prematurity ( ROP ) , effective study , test future large study .</brief_summary>
	<brief_title>Phase 1 Trial Bevacizumab Treatment Severe Retinopathy Prematurity</brief_title>
	<detailed_description>Despite promising initial result use empirical dos bevacizumab base half adult dose treatment acute severe ROP , little know low dos bevacizumab ROP . An increase number ophthalmologist treat premature infant severe ROP use bevacizumab . Given potential systemic ocular adverse effect intravitreal bevacizumab injection , determine lower effective dose bevacizumab important next step . The propose study test progressively low dos find dose take forward future large study .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Retinopathy Prematurity</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Type 1 ROP ; define : Zone I , stage ROP plus disease , Zone I , stage 3 ROP without plus disease , Zone II , stage 2 3 ROP plus disease 2 . No previous treatment ROP study eye ; previous bevacizumab treatment nonstudy eye The following exclusion apply study eye : 1 . Nasolacrimal duct obstruction 2 . Major ocular anomaly ( e.g. , cataract , coloboma ) 3 . Any opacity precludes adequate view retina If purulent ocular discharge present either eye , infant ineligible .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Retinopathy Prematurity</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>ROP</keyword>
</DOC>